AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23736357 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental policies supporting family meals
Number of subjects: 0
Study 23737404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (100 mg single oral dose)
Number of subjects: 40
Study 23737404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide in patients with ESRD
Number of subjects: 40
Study 23737404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide in patients with mild-to-moderate renal impairment
Number of subjects: 40
Study 23737404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide in patients with severe renal impairment
Number of subjects: 40
Study 23737404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide in patients on hemodialysis
Number of subjects: 40
Study 23738544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab for 26 weeks (trial 1)
Number of subjects: 37
Study 23738544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab for 26 weeks (trial 2)
Number of subjects: 37
Study 23738544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (both trials)
Number of subjects: 37
Study 23738544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (trial 1)
Number of subjects: 37
Study 23738760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transplant infusion of autologous MSC
Number of subjects: 2
Study 23738760 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy without basiliximab
Number of subjects: 2
Study 23738760 — intervention group
Group type: COMPARATOR
Intervention: Control group (not given MSC)
Number of subjects: 2
Study 23739141 — intervention group
Group type: EXPERIMENTAL
Intervention: EVR group (n = 76)
Number of subjects: 144
Study 23739141 — intervention group
Group type: COMPARATOR
Intervention: Non-EVR control group (n = 68)
Number of subjects: 144
Study 23739141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir use
Number of subjects: 144
Study 23739218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose assessment
Number of subjects: 226
Study 23739218 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 226
Study 23739218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose >7.0 mmol/l
Number of subjects: 226
Study 23739218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose between 6.1 and 7.0 mmol/l
Number of subjects: 226
Study 23739218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose <6.1 mmol/l
Number of subjects: 226
Study 23739725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways to Health obesity prevention program
Number of subjects: 0
Study 23740195 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) trial
Number of subjects: 0
Study 23740728 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme immunoassay kit detecting serum IgA antibody to glycopeptidolipid core antigen from MAC
Number of subjects: 0
Study 23740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet augmented ultrasound
Number of subjects: 52
Study 23740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate classifier
Number of subjects: 52
Study 23740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical modelling of wavelet coefficients
Number of subjects: 52
Study 23741398 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic insertions containing HLA-DRB5, DRB1 and DQA1/DRA genes in the MHC region (chromosome 6p21.3)
Number of subjects: 994
Study 23741398 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental insertion on chromosome 1 containing NBPF4, NBPF5, STXMP3, CLCC1, and GPSM2 genes
Number of subjects: 994
Study 23741398 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental deletions spanning PRR20, PCDH17 and PCH68 genes on chromosome 13
Number of subjects: 994
Study 23741398 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic insertion on chromosome 17 containing NSF, ARL17 and LRRC37A genes
Number of subjects: 994
Study 23742705 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-word test
Number of subjects: 620
Study 23742705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive disorders examination test
Number of subjects: 620
Study 23742705 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal fluency test
Number of subjects: 620
Study 23742705 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory consultation at University Hospital
Number of subjects: 620
Study 23743475 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-α (IFNα)
Number of subjects: 0
Study 23743475 — intervention group
Group type: EXPERIMENTAL
Intervention: New generation of HCV-specific antiviral drugs
Number of subjects: 0
Study 23744173 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 27
Study 23744173 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 27
Study 23744173 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 27
Study 23744173 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab vs Etanercept
Number of subjects: 27
Study 23744173 — intervention group
Group type: COMPARATOR
Intervention: Infliximab vs Etanercept
Number of subjects: 27
Study 23744583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiation therapy (CRT)
Number of subjects: 102
Study 23745006 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype A (low MA turnover and normal RT)
Number of subjects: 410
Study 23745006 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype B (low MA turnover and increased central RT)
Number of subjects: 410
Study 23745006 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype C (high MA turnover)
Number of subjects: 410
Study 23745581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF therapy
Number of subjects: 223
Study 23746612 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes with visible RNFL defects
Number of subjects: 66
Study 23746612 — intervention group
Group type: COMPARATOR
Intervention: Healthy eyes
Number of subjects: 66
Study 23746612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectors with visible RNFL defects in glaucomatous eyes
Number of subjects: 66
Study 23746612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectors without visible RNFL defects in glaucomatous eyes
Number of subjects: 66
Study 23746966 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC1992371A (oral aurora kinase inhibitor) at maximum tolerated doses of 37 mg/m(2)/day (days 1-3 and 8-10)
Number of subjects: 75
Study 23746966 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC1992371A (oral aurora kinase inhibitor) at maximum tolerated doses of 28 mg/m(2)/day (days 1-6)
Number of subjects: 75
Study 23746988 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography surveillance
Number of subjects: 243
Study 23747159 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 137
Study 23747159 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 137
Study 23748484 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 1140
Study 23748484 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1140
Study 23748977 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache occurrence in males
Number of subjects: 4431
Study 23748977 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache occurrence in females
Number of subjects: 4431
Study 23748977 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache associated with IS or TIA in posterior cerebral territory
Number of subjects: 4431
Study 23748977 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache associated with IS or TIA in vertebrobasilar arteries
Number of subjects: 4431
Study 23748977 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache occurrence related to lesion size
Number of subjects: 4431
Study 23748977 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for headache during CVE
Number of subjects: 4431
Study 23749683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (ICT)
Number of subjects: 393
Study 23749683 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT combined with gemtuzumab ozogamicin (ICT+GO)
Number of subjects: 393
Study 23749683 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 393
Study 23749683 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 393
Study 23749683 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDAC)
Number of subjects: 393
Study 23750331 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg) with THC/CBD spray (10.8/10 mg)
Number of subjects: 36
Study 23750331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg) with THC/CBD spray (10.8/10 mg)
Number of subjects: 36
Study 23750331 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg) with THC/CBD spray (10.8/10 mg)
Number of subjects: 36
Study 23751980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) - aspirin plus an NAAA
Number of subjects: 28696
Study 23751980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 28696
Study 23751980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaspirin antiplatelet agents (NAAAs)
Number of subjects: 28696
Study 23751980 — intervention group
Group type: COMPARATOR
Intervention: Nonusers (no antiplatelet drugs)
Number of subjects: 28696
Study 23752171 — intervention group
Group type: COMPARATOR
Intervention: 2 annual preventive visits (LoR)
Number of subjects: 5117
Study 23752171 — intervention group
Group type: COMPARATOR
Intervention: 1 annual preventive visit (LoR)
Number of subjects: 5117
Study 23752171 — intervention group
Group type: COMPARATOR
Intervention: 2 annual preventive visits (HiR)
Number of subjects: 5117
Study 23752171 — intervention group
Group type: COMPARATOR
Intervention: 1 annual preventive visit (HiR)
Number of subjects: 5117
Study 23752175 — intervention group
Group type: EXPERIMENTAL
Intervention: KPT-276
Number of subjects: 12
Study 23753021 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine followed by consolidation with (90)Y-ibritumomab tiuxetan
Number of subjects: 30
Study 23753021 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation therapy with (90)Y-ibritumomab tiuxetan
Number of subjects: 30
Study 23753021 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment
Number of subjects: 30
Study 23753028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, gemcitabine and oxaliplatin
Number of subjects: 49
Study 23753030 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab infusions and intensive chemotherapy (high-dose methotrexate, fractionated ifosfamide/cyclophosphamide, other drugs in rotation, intrathecal chemoprophylaxis)
Number of subjects: 105
Study 23753030 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab infusions and intensive chemotherapy
Number of subjects: 105
Study 23753102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (maximum oxygen uptake, mL/kg/min) measured with a maximal cycle ergometer test
Number of subjects: 341
Study 23753102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (maximum oxygen uptake, mL/kg/min)
Number of subjects: 341
Study 23753102 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle counseling (not associated with fitness)
Number of subjects: 341
Study 23754469 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin-thrombin matrix
Number of subjects: 20
Study 23754575 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously)
Number of subjects: 56
Study 23754575 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) with rifampin (CYP3A inducer)
Number of subjects: 56
Study 23754575 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) with ketoconazole (CYP3A inhibitor)
Number of subjects: 56
Study 23754628 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone (Control)
Number of subjects: 562
Study 23754824 — intervention group
Group type: EXPERIMENTAL
Intervention: Food reinforcement
Number of subjects: 166
Study 23754824 — intervention group
Group type: EXPERIMENTAL
Intervention: Household income
Number of subjects: 166
Study 23754824 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect effect of household income
Number of subjects: 166
Study 23754824 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level as proxy for SES
Number of subjects: 166
Study 23756334 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic arousals during sleep (measured by autonomic arousal index, AAI)
Number of subjects: 780
Study 23756334 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic arousals during sleep (measured by AAI)
Number of subjects: 780
Study 23756334 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased AAI
Number of subjects: 780
Study 23756764 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg, 20 mg, 25 mg) and Sorafenib (200 mg, 400 mg) given orally once daily for 28 days (1 cycle).
Number of subjects: 41
Study 23756764 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Sorafenib treatment.
Number of subjects: 41
Study 23756775 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency repairs
Number of subjects: 10976
Study 23756775 — intervention group
Group type: COMPARATOR
Intervention: Elective repairs
Number of subjects: 10976
Study 23757434 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 1879
Study 23757434 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitored blood glucose (BG)
Number of subjects: 1879
Study 23757434 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated Average Glucose (AG)
Number of subjects: 1879
Study 23758300 — intervention group
Group type: EXPERIMENTAL
Intervention: CE+EUS
Number of subjects: 387
Study 23758300 — intervention group
Group type: COMPARATOR
Intervention: CE
Number of subjects: 387
Study 23758943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypovitaminosis D
Number of subjects: 9305
Study 23759033 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-seeking overweight youth (parent-reported HRQoL)
Number of subjects: 137
Study 23759033 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-seeking overweight youth (self-reported HRQoL)
Number of subjects: 137
Study 23759033 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-seeking status
Number of subjects: 137
Study 23759033 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived overweight status
Number of subjects: 137
Study 23760428 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (selective serotonin reuptake inhibitor)
Number of subjects: 0
Study 23760428 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0
Study 23760428 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 23760428 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 supplementation
Number of subjects: 0
Study 23760428 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (serotonin-norepinephrine reuptake inhibitor)
Number of subjects: 0
Study 23760428 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral estradiol
Number of subjects: 0
Study 23760428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23760766 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week inpatient program combining rehabilitative treatment and preventive, psychosocial, child-centered interventions
Number of subjects: 116
Study 23761092 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraoperative optical coherence tomography (OCT) measurements of anterior lens capsule position after removing the crystalline lens and after implanting a capsular tension ring (CTR).
Number of subjects: 70
Study 23761092 — intervention group
Group type: COMPARATOR
Intervention: Preoperative ACD measurements.
Number of subjects: 70
Study 23761380 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS assay for serum cortisol analysis
Number of subjects: 320
Study 23761380 — intervention group
Group type: COMPARATOR
Intervention: Immunoassays (Roche and Abbott)
Number of subjects: 320
Study 23761380 — intervention group
Group type: COMPARATOR
Intervention: GC-MS assay
Number of subjects: 320
Study 23761401 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating progenitor cells (PCs) with higher serum SDF-1α levels and reduced spontaneous motility in an in vitro migration assay.
Number of subjects: 172
Study 23761401 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of PCs non-migrated towards vehicle or SDF-1α.
Number of subjects: 172
Study 23761401 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum SDF-1α levels.
Number of subjects: 172
Study 23761422 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (r-hGH) therapy
Number of subjects: 103
Study 23761643 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-spot urine specimens (morning, afternoon, evening, overnight)
Number of subjects: 407
Study 23761643 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-spot urine specimens (overnight)
Number of subjects: 407
Study 23761643 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h urine samples
Number of subjects: 407
Study 23762229 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent flu vaccine (AdimFlu-S®) 15 mcg of hemagglutinin for each strain/0.5 mL
Number of subjects: 46
Study 23763450 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological Test Battery (NTB)
Number of subjects: 0
Study 23763450 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cog)
Number of subjects: 0
Study 23763917 — intervention group
Group type: EXPERIMENTAL
Intervention: Barasertib (800 mg, 1000 mg, 1200 mg) plus low-dose cytosine arabinoside (LDAC) 20 mg (subcutaneous injection twice daily for 10 days) administered in 28-day cycles.
Number of subjects: 22
Study 23764537 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 27
Study 23764909 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular dysfunction and elevated troponin level
Number of subjects: 1515
Study 23764909 — intervention group
Group type: EXPERIMENTAL
Intervention: Either right ventricular dysfunction or elevated troponin level
Number of subjects: 1515
Study 23764909 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall model including both dysfunction and injury
Number of subjects: 1515
Study 23764909 — intervention group
Group type: EXPERIMENTAL
Intervention: No dysfunction or injury
Number of subjects: 1515
Study 23765437 — intervention group
Group type: EXPERIMENTAL
Intervention: VKA therapy
Number of subjects: 963
Study 23765437 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall occurrence of in-hospital major adverse cardiac events
Number of subjects: 963
Study 23765437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding complications
Number of subjects: 963
Study 23765437 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment
Number of subjects: 963
Study 23765437 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender/treatment with gpIIb/IIIa-antagonists
Number of subjects: 963
Study 23765752 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 92
Study 23765752 — intervention group
Group type: COMPARATOR
Intervention: MHOS
Number of subjects: 92
Study 23768574 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual allergen immunotherapy (specific dosage and duration not available)
Number of subjects: 0
Study 23769088 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) + reduced exposure tacrolimus (rTAC)
Number of subjects: 719
Study 23769088 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus (TAC)
Number of subjects: 719
Study 23769498 — intervention group
Group type: EXPERIMENTAL
Intervention: Target fortified breast milk (fat: 4.4 g, protein: 3 g, carbohydrates: 8.8 g per 100 mL)
Number of subjects: 20
Study 23769498 — intervention group
Group type: COMPARATOR
Intervention: Routine fortification of breast milk
Number of subjects: 20
Study 23770158 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin (250 mg oral, 125 mg tablets twice a day; a 1125-mg loading dose on day 1)
Number of subjects: 57
Study 23770972 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day aspirin
Number of subjects: 299
Study 23770972 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day aspirin plus 40 mg/day atorvastatin
Number of subjects: 299
Study 23770972 — intervention group
Group type: COMPARATOR
Intervention: X-CGD patients
Number of subjects: 299
Study 23770972 — intervention group
Group type: COMPARATOR
Intervention: T2D patients
Number of subjects: 299
Study 23770972 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro study
Number of subjects: 299
Study 23771742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory surgery
Number of subjects: 0
Study 23772042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline as monotherapy
Number of subjects: 254
Study 23772042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline as combination therapy
Number of subjects: 254
Study 23772042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline for nosocomial infections
Number of subjects: 254
Study 23772042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline for patients with APACHE II score >15
Number of subjects: 254
Study 23772042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline for patients with SOFA score ≥ 7
Number of subjects: 254
Study 23772045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (used alone or in combination)
Number of subjects: 1039
Study 23772047 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg plus 50 mg twice daily) for a mean duration of 11.1 ± 6.4 days
Number of subjects: 1782
Study 23773637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation (MSCT)
Number of subjects: 3